Posted by Michael Wonder on 09 Nov 2023
PHARMAC asked to reconsider funding RSV drug for at risk babies
9 November 2023 - Paediatricians and neonatal experts are pleading with PHARMAC to rethink its decision to stop funding a drug that prevents at risk babies from being hospitalised with a deadly lung infection.
The drug funding agency agreed palivizumab had lowered the rate of hospitalisations for respiratory syncytial virus but said there was "limited evidence" that it had reduced deaths.
